diagnost anim health
commerci anim health
vaccin product also provid product
servic relat biodevic diagnost
tool genet
requir disclosur end report
zoeti companion three drive reiter buy pt
rais
view current cl king meet event calendar coverag univers
calendar
zoeti good quarter driven companion anim revenu
expect threesimparica cytopoint
apoquelbeat expect core thesi zoeti grow
revenu via exist companion anim product maintain stabl
perform livestock busi drive earn growth
effici initi base stabl strong cash flow
dividend share repurchas view stabl long-term grower
attract market reiter buy rate rais price target
result report revenu y/i versu
year-ago period street
respect adjust ep versu last year
y/i top street estim net
foreign exchang revenu grew net incom grew
outlook zoeti updat revenu guidanc
midpoint right line
beat increas ep guidanc
rais adjust ep impli
ep number stay intact
three companion drug dermatolog portfolio apoquel
cytopoint sale although zoeti
maintain languag peak sale think could
perhap even higher simparica revenu
year year
pipelin zoeti provid addit color combo call simparica
ingelheim merck nr anim health may also tripl combo
shouldnt matter market huge estim
zoeti under-index categori suspect compani
biologic-bas osteoarthr pain drug think recept
product would strong
 sale sale
driven growth companion anim product aid product
cytopoint apoquel simparica zoeti note competit headwind
certain in-lin product sale livestock grew driven
poultri off-set weak cattl
sale sale constant
currenc sale companion anim product grew
constant currenc account strong sale cytopoint
apoquel stronghold simparica livestock grew constant
currenc driven speci zoeti specif call time
benefit china growth cattl brazil strength fish global
posit top-lin result pilot effect studi
atop dermat biolog drug move field effect
studi determin kindr make superior claim
believ program remain track launch
although timelin alway tough kindr attempt go
superior claim remind investor zoeti abil make
label expans cytopoint
model increas respect revenu estim
also
rais adjust ep forecast
respect addit rais revenu
adjust ep project
price new price target round base
price-to-earnings multipl vs previous revis adjust ep
estim increas multipl simpli reflect
risk achiev price target
price concess competit
strong growth prospect outsid
page
